Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Indoco Remedies Ltd

INDOCO.NS ✗ NOT COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: HOLD

Last Close

$2.29

▼ -3.14%

Market Cap $211.14M · Vol 53.70K

Key Metrics

P/E Ratio

684.97

FWD: 33.87

Market Cap

$211.14M

Micro Cap

Div Yield

0.09%

Annual dividend

EPS Growth

+130.91%

YoY

RSI (14)

44.34

Momentum

Beta

1.63

vs Market

52W High

$3.47

39.19% below

52W Low

$1.69

33.18% above

Volume

53.70K

Avg 260.66K

P/B

N/A

Price-to-book

ROE

-9.40%

Return on equity

Free Float

39.11%

Public shares

Shariah Compliance8 STANDARDS

✗ Indoco Remedies Ltd (INDOCO.NS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INDOCO.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.21%

-9.95%

+10.10%

+7.92%

YTD

-6.57%

-21.59%

-41.55%

-51.30%

Financials & Valuation

TTM · Annual

Total Revenue	$197.45M
Net Income	$-10,561,007.00
Revenue Growth (YoY)	+6.76%
Gross Margin	63.79%
Operating Margin	N/A
Net Profit Margin	-5.16%
ROE	-9.40%
ROA · ROIC	-4.24% · N/A

P/E Ratio	684.97
Forward P/E (FY1)	33.87
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+130.91%
Outstanding Shares	92.17M

Technical Indicators

50-Day SMA	$2.44
200-Day SMA	$2.33
RSI (14)	44.34
Beta	1.63
52-Week High	$3.47
52-Week Low	$1.69

Volume Today	53.70K
Avg Daily Volume (30D)	260.66K
Relative Volume	0.21x
Volatility (10D)	29.47
Volatility (30D)	38.77
Free Float	39.11%

Analyst Consensus

HOLD

Current Price $2.29

Mean Target $2.74

52W Low$1.69 52W High$3.47

Current

Target

$1.69 $3.47

Current Analyst target

+19.64% upside potential · 3 analysts

Identifiers

ExchangeNSE India

FIGIBBG001SN8B12

ISININE873D01024

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -0.67% JNJ Johnson & Johnson +1.04% ABBV Abbvie Inc -0.17% NVS Novartis AG -0.53% NOVN.S Novartis AG -0.52%

Company Profile

Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.